Retatrutide Side Effects
Retatrutide's side effect profile is dose-dependent and largely predictable from its mechanism. It activates three receptors — GIP, GLP-1 and glucagon — and most of what participants reported in trials follows directly from the GLP-1 component, which is the one with the largest existing safety literature behind it.
Gastrointestinal effects: the dominant category
Nausea, vomiting, diarrhea and constipation were the most frequently reported adverse events across every dose arm, and their frequency rose with dose. In the Phase 2 obesity trial the majority were graded mild to moderate, and they were concentrated in the escalation phase rather than spread evenly across the 48 weeks.
| Effect | Pattern in trials | Typical course |
|---|---|---|
| Nausea | Most common; frequency rises with dose | Worst in the days after a dose increase, then settles |
| Vomiting | Less common than nausea, same dose relationship | Usually early in escalation |
| Diarrhea | Common across arms | Often intermittent |
| Constipation | Common; sometimes alternates with diarrhea | Persists more than nausea does |
| Reduced appetite | Near-universal — this is the intended effect | Sustained |
Discontinuation due to adverse events was higher in the 12 mg arm than at lower doses, which is part of why the 8 mg dose is often described as the better effect-to-tolerability point: it produced nearly the same weight loss as 12 mg with fewer complaints. Details of the escalation schedule are in our dosage guide.
Cardiovascular effects
Trials reported modest heart rate increases, on the order of a few beats per minute on average. This is consistent across the incretin class and is not unique to retatrutide. Phase 2 did not surface a signal of serious cardiac events, but Phase 2 is not powered to detect one — cardiovascular outcome data is what larger and longer trials produce.
What the glucagon component adds
This is the part that distinguishes retatrutide from tirzepatide and semaglutide. Glucagon receptor activation increases energy expenditure and mobilizes fat from the liver, which contributes to the larger weight reductions — and it is also why trial protocols monitored liver enzymes and heart rate more closely than a pure GLP-1 study would.
Reported findings on liver parameters in Phase 2 were favorable, with reductions in liver fat rather than injury signals. The honest framing is that this receptor combination has less accumulated human exposure than the GLP-1 mechanism, so its long-term profile is less well characterized, not that a problem has been identified.
Serious but uncommon concerns
These come from the class rather than from retatrutide-specific findings, and they are the ones clinicians screen for with related approved drugs:
- Pancreatitis — appears in the safety data for the incretin class; a personal history of it is treated as a contraindication.
- Gallbladder disease — rapid weight loss increases gallstone risk independently of any drug, and the class has a documented association.
- Medullary thyroid carcinoma — a boxed warning on approved GLP-1 agonists based on rodent thyroid C-cell tumors; personal or family history, and MEN 2 syndrome, are exclusions.
- Diabetic retinopathy progression — observed with rapid glycaemic improvement in the class; relevant to anyone with existing retinopathy.
- Hypoglycaemia — low risk alone, higher when combined with insulin or sulfonylureas.
Lean mass loss
Not usually listed as a side effect, but it belongs here. Large rapid weight reduction costs lean tissue alongside fat. A body-composition substudy — run in the phase 2 type 2 diabetes trial rather than the obesity trial, in 189 participants — found the loss came predominantly from fat, with a fat-loss index the authors described as consistent with other weight-loss treatments. Read that carefully: predominantly fat, but not more lean-sparing than its competitors. Resistance training and adequate protein are the standard mitigations, and no compound substitutes for either.
What is not yet known
Retatrutide is in Phase 3. That means there is no long-term human safety data beyond the trial windows completed so far, no cardiovascular outcome trial result, and no data on use beyond a couple of years. Anyone describing its long-term safety with confidence is describing something that has not been measured.
Retatrutide (RTA) — 10 mg — American Peptides
Not FDA approved; sold for laboratory research only. Batch-tested with HPLC and mass spectrometry, COA provided.
We may earn a commission if you buy through this link (at no extra cost to you). Sold for research purposes only.
Frequently asked questions
What are the most common retatrutide side effects?
Gastrointestinal effects dominate: nausea, vomiting, diarrhea and constipation. In the Phase 2 obesity trial these were reported by a substantial share of participants at higher doses, were mostly mild to moderate, and clustered around dose escalations rather than occurring at random.
Does retatrutide raise heart rate?
Yes, modestly. Trials reported small increases in heart rate, consistent with what has been seen across the GLP-1 and multi-agonist class. It was not associated with a signal of serious cardiac events in the Phase 2 data, but it is a documented effect rather than an absent one.
How do you reduce retatrutide side effects?
The mitigation used in trial design is slow titration: start low, hold each dose level for about four weeks, and step up only after tolerating the current level. Most tolerability problems in practice come from escalating too quickly or starting at a high dose.
Does the glucagon component cause additional side effects?
Glucagon receptor activation raises energy expenditure and mobilizes hepatic fat, and it is the main mechanistic difference from tirzepatide. Trials monitored liver enzymes and heart rate closely for this reason. Both were watched rather than problematic in Phase 2, but longer-term data is what Phase 3 exists to produce.
Who should not take retatrutide?
Retatrutide is not approved for anyone, so the strict answer is that no one has an approved indication. The class-level contraindications that apply to related approved drugs — personal or family history of medullary thyroid carcinoma, MEN 2 syndrome, prior pancreatitis, and pregnancy — are the ones clinicians apply to this mechanism.
Sources
- Jastreboff AM et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine, 2023;389(6):514–526. PubMed
- Rosenstock J et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. The Lancet, 2023;402(10401):529–544. PubMed
- Sanyal AJ et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine, 2024;30(7):2037–2048. PubMed
- Coskun T et al. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. The Lancet Diabetes & Endocrinology, 2025;13(8):674–684. PubMed
- Class warnings for approved GLP-1 receptor agonists: Wegovy (semaglutide), Drugs@FDA and Zepbound (tirzepatide), Drugs@FDA.
Related guides
- Retatrutide dosage and titration chart
- Retatrutide cost and how to get it
- Where to buy retatrutide: supplier vetting
- Are peptides safe?